Table 1 Characteristic of included studies
Author | Year | Country | Implant | Device | Number | Age | BMI | Outcomes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
ABN | CONV | ABN | CONV | ABN | CONV | ||||||
Ali | 2021 | Australia | Legion (Smith and Nephew) | KneeAlign 2 | 81 | 78 | 68.1 | 68.2 | NA | NA | KOOS WOMAC Complications |
NCT03111407 | 2021 | Spain | NA | iASSIST | 44 | 26 | 67.3 ± 7.9 | 70.3 ± 7.4 | 30.4 ± 5.5 | 30.7 ± 4.6 | MA KSS EQ-5D Complications |
Kosuke | 2021 | Japan | Persona (Zimmer) | iASSIST | 42 | 41 | 73.3 ± 9.0 | 76.1 ± 9.0 | NA | NA | KSS OKS EQ-5D CFA CTA TS OT BL |
Minoda | 2020 | Japan | Vanguard (Zimmer) | KneeAlign 2 | 45 | 45 | 76 ± 5 | 74 ± 7 | 26.5 ± 4.4 | 27.4 ± 4.2 | MA CFA CTA OT KSS EQ-5D |
Xu | 2019 | China | Genesis II (Smith and Nephew) | i-Join | 39 | 40 | 65.3 ± 6.8 | 65.3 ± 7.6 | NA | NA | MA CFA OT BL Complications |
Kinney | 2018 | America | Persona (Zimmer) | iASSIST | 25 | 25 | 66.4 ± 2.3 | 65 ± 2.0 | 30.4 ± 1.2 | 31.1 ± 1.2 | MA CFA CTA OT BL Complications |
Ikawa | 2017 | Japan | Vanguard (Zimmer) | KneeAlign 2 | 121 | 120 | 74 ± 6.8 | 74.1 ± 6.8 | 26.1 ± 3.7 | 26.8 ± 4.1 | MA CFA OT BL |
Gharaibeh | 2017 | Australia | Legion (Smith and Nephew) | KneeAlign | 89 | 90 | 69.2 ± 8.7 | 69 ± 8.3 | 29.6 ± 5.4 | 29.2 ± 4.8 | MA CFA CTA TS |
Thiengwittayaporn | 2016 | Thailand | NexGen HiFlex (Zimmer) | iASSIST | 40 | 40 | 68.0 ± 8.0 | 65.9 ± 6.3 | 26.6 ± 3.7 | 26.6 ± 3.7 | MA CFA CTA TS OT BL |
Nam | 2014 | America | NA | KneeAlign | 47 | 47 | 67.1 ± 7.5 | 66.1 ± 10.1 | 31.1 ± 5.9 | 31.2 ± 5.6 | MA CFA CTA TS |